Sio Capital Management LLC Reduces Position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA)

Sio Capital Management LLC decreased its position in shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 9.2% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 123,797 shares of the biopharmaceutical company’s stock after selling 12,528 shares during the period. Sio Capital Management LLC owned 0.22% of Vanda Pharmaceuticals worth $841,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in VNDA. Millennium Management LLC increased its position in Vanda Pharmaceuticals by 1,089.5% during the fourth quarter. Millennium Management LLC now owns 1,783,745 shares of the biopharmaceutical company’s stock worth $13,182,000 after buying an additional 1,633,788 shares during the period. Bank of America Corp DE increased its position in Vanda Pharmaceuticals by 471.1% during the first quarter. Bank of America Corp DE now owns 1,631,140 shares of the biopharmaceutical company’s stock worth $11,075,000 after buying an additional 1,345,529 shares during the period. Pictet Asset Management SA increased its position in Vanda Pharmaceuticals by 166.7% during the first quarter. Pictet Asset Management SA now owns 1,217,817 shares of the biopharmaceutical company’s stock worth $8,269,000 after buying an additional 761,200 shares during the period. State Street Corp increased its position in Vanda Pharmaceuticals by 22.1% during the first quarter. State Street Corp now owns 4,063,298 shares of the biopharmaceutical company’s stock worth $45,956,000 after buying an additional 735,865 shares during the period. Finally, Allspring Global Investments Holdings LLC increased its position in Vanda Pharmaceuticals by 243.9% during the first quarter. Allspring Global Investments Holdings LLC now owns 797,392 shares of the biopharmaceutical company’s stock worth $5,414,000 after buying an additional 565,510 shares during the period. Institutional investors and hedge funds own 97.92% of the company’s stock.

Vanda Pharmaceuticals Trading Up 1.1 %

NASDAQ:VNDA opened at $4.62 on Friday. The firm has a market cap of $265.70 million, a P/E ratio of 17.11 and a beta of 0.70. The stock’s 50 day simple moving average is $5.87 and its 200-day simple moving average is $6.25. Vanda Pharmaceuticals Inc. has a 12-month low of $4.15 and a 12-month high of $11.04.

Vanda Pharmaceuticals (NASDAQ:VNDA) last released its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.16. The business had revenue of $46.06 million for the quarter, compared to analyst estimates of $49.00 million. Vanda Pharmaceuticals had a return on equity of 2.81% and a net margin of 6.25%.

Insider Activity

In other news, SVP Timothy Williams sold 14,600 shares of the business’s stock in a transaction that occurred on Tuesday, June 13th. The stock was sold at an average price of $6.56, for a total value of $95,776.00. Following the transaction, the senior vice president now owns 88,913 shares of the company’s stock, valued at $583,269.28. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. In related news, SVP Timothy Williams sold 14,600 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Tuesday, June 13th. The stock was sold at an average price of $6.56, for a total value of $95,776.00. Following the sale, the senior vice president now directly owns 88,913 shares in the company, valued at $583,269.28. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Stephen Ray Mitchell sold 6,500 shares of Vanda Pharmaceuticals stock in a transaction that occurred on Thursday, August 10th. The shares were sold at an average price of $6.05, for a total value of $39,325.00. Following the completion of the sale, the director now owns 29,328 shares in the company, valued at $177,434.40. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 43,036 shares of company stock valued at $271,425. Company insiders own 7.70% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on Vanda Pharmaceuticals in a research report on Thursday, August 17th. They set a “buy” rating on the stock.

Vanda Pharmaceuticals Profile

Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia.